Djulbegovic B. and Hozo I. "When should potentially false research findings be considered acceptable?" PLoS Medicine (accepted - in press)

Stem Cell Trialists Group. "Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs. bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration." Bone Marrow Transplant (2006); 38:539-546.

Kumar A, Soares PH, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, and Djulbegovic B, "What is the probability that a new treatment for cancer in children will be superior to an established treatment? An observational study of randomised controlled trials conducted by the Children's Oncology Group.", British Medical Journal (2005); 331; 1295-1301.

Pudar Hozo S, Djulbegovic B, Hozo I, “Estimating the mean and variance from the median, range, and the size of a sample.”  BMC Medical Research Methodology 5:13 (2005).

Stem Cell Trialists Group.  “Allogeneic Peripheral Blood Stem Cell Transplant vs. Bone Marrow Transplant in the Management of Hematological Malignancies:  An Individual Patient Data Meta-Analysis of 9 Randomized Trials."  Journal of Clinical Oncology  23.22 (2005), 5074-87.

Hozo I, Djulbegovic B, Clark O and Lyman G, “Use of re-randomized data in meta-analysis” BMC Medical Research Methodology 5:17 (2005).

Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B “Evaluation of New Treatments in Radiation Oncology: Are They Better Than Standard Treatments?” JAMA (Journal of the American Medical Association) 293.8 (2005), 970-78.

Djulbegovic B, Hozo I. “At what degree of belief in research hypothesis a trial in humans is justified?" J Eval Clin Practice (2002), 8: 269-276.

Djulbegovic B, Adams J, Lyman G, Lacevic M, Hozo I, Greenwich M, and Bennett C. “Evaluation and Appraisal of Randomized Controlled Trials in Myeloma.” Annals Oncol (2001), 12: 1-7.

Djulbegovic B, Hozo I and Lyman G. “Linking Evidence-based Medicine Therapeutic Summary Measures to Clinical Decision Analysis.” MedGenMed, January 13, 2000 (20 pages). 

Djulbegovic B, Hozo I, Lyman G.H. “Talking about treatment.” Ann Intern Med (2000) 132: 93-94.

Hozo I, Djulbegovic B. "Using Internet to Calculate Clinical Action Thresholds." C Biomed Res 1999; 32:168-185.

Djulbegovic B, Hozo I, McMasters K, Schwartz A. "Regret in Medical Decision Making."   Med Hypotheses (1999) 53:253-259.

Hozo I, B. Djulbegovic, "Computer program for the Diagnosis and Treatment of   Polycythemia Rubra Vera." M.D. Computing. (1999) 16:83-89.

Djulbegovic B and Hozo I. "Acting on evidence can only be done within the context of decision analysis." BMJ (1998; July 29) (http://www.bmj.com/cgi/eletters/317/7151/139).

Djulbegovic B, Hozo I, Fields K, Sullivan D. "High Dose Chemotherapy in the Adjuvant  Treatment of Breast Cancer: Benefit/Risk Analysis." Cancer Control (1998) 5:26-37.

Hozo I, B. Djulbegovic, “Calculating confidence intervals for threshold and posttest  probabilities." M.D. Computing. (1998) 15:110-115.

Hozo I, ``Inclusion of the poset homology into the Lie algebra homology.'' Journal of  Pure and Applied Algebra. (1996) 111: 169-180.

B.Djulbegovic, Hozo I, I. Abdomerovic, S. Pudar-Hozo, ``Diagnostic Entropy as a function of therapeutic benefit/risk ratio'' , Medical Hypothesis (1995) 45: 503-509.

Hozo I, ``The eigenvalues of the Laplacian of the homology of the Lie algebra corresponding to a poset'', Electronic Journal of Combinatorics Vol. 2 (1995) #R14 (42 pages).

Hozo I and H.I. Miller, ``On Riemann's Theorem About Conditionally Convergent Series'', Matematicki Vesnik (Belgrade), (1986) 38: 279-283.